Analyst Price Targets — CAR
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| September 11, 2026 11:51 am | Andrew Percoco | Morgan Stanley | $95.00 | $126.74 | TheFly | Avis Budget price target lowered to $95 from $99 at Morgan Stanley |
| July 24, 2026 10:15 am | — | Goldman Sachs | $95.00 | $159.04 | TheFly | Avis Budget price target raised to $95 from $85 at Goldman Sachs |
| June 8, 2026 7:51 am | Dan Levy | Barclays | $160.00 | $176.79 | StreetInsider | Barclays Upgrades Avis Budget Group (CAR) to Equalweight |
| May 20, 2026 11:52 am | — | Morgan Stanley | $99.00 | $151.08 | TheFly | Avis Budget price target raised to $99 from $97 at Morgan Stanley |
| May 8, 2026 3:01 pm | Christopher Stathoulopoulos | Susquehanna | $140.00 | $143.89 | TheFly | Avis Budget price target raised to $140 from $105 at Susquehanna |
| May 5, 2026 8:51 am | — | Barclays | $140.00 | $168.30 | TheFly | Avis Budget price target lowered to $140 from $150 at Barclays |
| May 1, 2026 11:19 am | Chris Woronka | Deutsche Bank | $125.00 | $180.67 | TheFly | Avis Budget price target lowered to $125 from $128 at Deutsche Bank |
| April 30, 2026 8:15 pm | — | Jefferies | $160.00 | $180.67 | TheFly | Jefferies downgrades Avis to Hold on 'technical overhangs' |
| February 23, 2026 11:44 am | — | Goldman Sachs | $85.00 | $96.47 | TheFly | Avis Budget price target lowered to $85 from $111 at Goldman Sachs |
| December 8, 2025 10:23 am | — | Morgan Stanley | $142.00 | $134.85 | TheFly | Avis Budget downgraded to Equal Weight from Overweight at Morgan Stanley |
Latest News for CAR
Cartesian Therapeutics maintains a 'Buy' rating, driven by advancing Descartes-08 cell therapy programs and imminent late-stage clinical catalysts. Topline results from the phase 3 AURORA study in AChR Ab+ Myasthenia Gravis are expected in Q1 2027, with a potential BLA filing in mid-2027. RNAC is expanding Descartes-08 into myositis indications and pursuing an in vivo CAR-T approach via a strategic WestGene…
Avis Budget (CAR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PARSIPPANY, N.J.--(BUSINESS WIRE)--Avis announced the expansion of Avis First to London Heathrow and Paris Charles de Gaulle airports, bringing its premium car rental service to more than 30 airport and city locations across North America and Europe. Available exclusively through the Avis mobile app, Avis First makes traveling easier and more efficient from the beginning to the end of every trip with coordinated…
First patient in fifth cohort exhibiting stable disease 90 days after treatment Multiple patients surviving more than one year, including one beyond two years, with no dose-limiting toxicities observed to date Patients in fifth cohort received 1×10⁷ CAR-positive cells/kg following lymphodepletion SAN JOSE, Calif., Oct. 26, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a…
TG Therapeutics, Inc. (NASDAQ: TGTX), today announced initial results from the Company's Phase 1 study evaluating azercabtagene zapreleucel (azer-cel), an inves
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CAR.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.